Business · Companies · 4 hrs ago
Canadian watchdog closes Express Scripts investigation without penalties
Canada’s Competition Bureau found insufficient evidence that Express Scripts abused its market position and closed its investigation without penalties.
Express Scripts Canada is the country’s largest pharmacy benefit manager, a middleman that processes prescription claims for insurers.
The investigation followed complaints about fees charged to pharmacies and networks that can require patients to use certain pharmacies to get reimbursed.
The bureau found that Express Scripts’ pharmacies handle a small share of prescriptions in Canada and that its preferred networks are not widely used.
Still, exclusive pharmacy networks could limit patients’ choice and make it harder for pharmacies outside those networks to stay in business.
The bureau said it may take enforcement action if new information shows that such networks break competition law.
Canada’s Competition Bureau has closed its investigation into Express Scripts Canada without finding enough evidence to conclude that the company abused a dominant position.
The bureau said its evidence did not show that the company’s fees harmed competition or that its preferred provider networks were an abuse of dominance.
It said exclusive pharmacy networks could raise competition issues in other cases and that it may take enforcement action if new information emerges.
The investigation followed complaints about fees charged to retail pharmacies and arrangements that could steer patients to particular pharmacies.
- Who
- The Competition Bureau investigated Express Scripts Canada, a pharmacy benefit manager.
- What
- The bureau closed its investigation without penalties, finding insufficient evidence of wrongdoing.
- When
- The bureau announced its conclusion on Monday, November 16, 2026.
- Where
- Canada.
- Why
- Complaints alleged that Express Scripts abused its market position through mandatory pharmacy fees and preferred provider networks.
Competition Bureau
Express Scripts Canada
Competition concerns
Competition Bureau
The bureau said exclusive preferred provider networks could raise competition issues in other cases.
Express Scripts Canada
Express Scripts said its role is to help make prescription drugs more affordable and accessible.
Company practices
Competition Bureau
The bureau found insufficient evidence to conclude that Express Scripts abused a dominant position.
Express Scripts Canada
The company said it remains focused on reliable access to medications, lowering costs and working with pharmacies.
The Competition Bureau began receiving complaints about Express Scripts, including claims about mandatory fees and preferred provider networks.
The bureau submitted concerns about exclusive preferred provider networks to an Ontario government consultation.
The bureau announced that it had closed its investigation without finding sufficient evidence of abuse of a dominant position.
- Investigation outcome
- Closed without penalties
- Company investigated
- Express Scripts Canada
- Evidence on dominance
- Insufficient to conclude that Express Scripts abused a dominant position
- Market evidence
- Express Scripts pharmacies accounted for a small share of prescriptions in Canada
- Network use
- The bureau found that Express Scripts’ preferred provider networks were not widely used in Canada
What people are saying
Based on the evidence gathered, the bureau found insufficient evidence at this time to conclude that Express Scripts abused a dominant position
If new information comes to light suggesting that a preferred provider network braises issues under the Competition Act, the bureau will not hesitate to take appropriate enforcement action.
ESC remains focused on supporting reliable access to medications for Canadians, lowering costs for patients and plan sponsors, and working constructively with pharmacies across Canada.